A systematic review on the effect of bevacizumab in exudative age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 3, 2010, Pages 451-452

  Schmucker, Christine ^a   Antes, Gerd ^a   Lelgemann, Monika ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

Age related macular degeneration; Bevacizumab; Efficacy; Safety

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; LETTER; OFF LABEL DRUG USE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY;

AGING; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EXUDATES AND TRANSUDATES; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 77949269454     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1249-5     Document Type: Letter

References (11)

1. ZF Bashshur A Schakal RN Hamam CP El Haibi RF Jaafar B Noureddin 2007 Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration Arch Ophthalmol 125 1357 1361 10.1001/archopht.125.10.1357 1:CAS:528:DC%2BD2sXht1aqurrO 17923543 (Pubitemid 47606600)
2. DM Brown M Michels PK Kaiser JS Heier JP Sy T Ianchulev 2009 Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57 69 10.1016/j.ophtha.2008.10.018 19118696
3. R Lazic N Gabric 2007 Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 245 68 73 10.1007/s00417-006-0466-4 1:CAS:528:DC%2BD28Xht1KgtrbP 17111146 (Pubitemid 46766732)
4. R Hahn S Sacu S Michels A Varga G Weigert W Geitzenauer P Vecsei-Marlovits U Schmidt-Erfurth 2007 Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degenereation Ophthalmologe 104 588 593 10.1007/s00347-007-1547-4 1:CAS:528:DC%2BD2sXotVOmtb4%3D 17564719
5. PJ Rosenfeld DM Brown JS Heier DS Boyer PK Kaiser CY Chung RY Kim MARINA Study Group 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431 10.1056/NEJMoa054481 1:CAS:528:DC%2BD28XhtVGgtr3M 17021318 (Pubitemid 44511557)
6. L Wu MA Martínez-Castellanos H Quiroz-Mercado JF Arevalo MH Berrocal ME Farah M Maia JA Roca FJ Rodriguez Pan American Collaborative Retina Group (PACORES) 2008 Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 81 87 10.1007/s00417-007- 0660-z 1:CAS:528:DC%2BD2sXhtlaqsbbP 17674014 (Pubitemid 350167096)
7. AE Fung PJ Rosenfeld E Reichel 2006 The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide Br J Ophthalmol 90 1344 1349 10.1136/bjo.2006.099598 1:STN:280: DC%2BD28nit1Sltw%3D%3D 16854824 (Pubitemid 44702055)
8. IVAN Study. www.controlled-trials.com. ISRCTN92166560. Accessed July 30, 2009
9. CATT Study. www.clinicaltrials.gov. NCT00593450. Accessed July 30, 2009
10. EQUAL Study. http://apps.who.int/trialsearch/. NTR1331. Accessed July 30, 2009
11. VIBERA Study. www.clinicaltrials.gov. NCT00559715. Accessed July 30, 2009